LCID
Lucid Group, Inc.
LCID offers stronger valuation, but that advantage does not outweigh its weaker overall profile.
SBH
Sally Beauty Holdings, Inc.
SBH has the edge over LCID overall, supported by lower modeled downside.
LCID Fundamentals
| Metric | Status |
|---|---|
| Healthy | |
| Weak | |
| Weak | |
| Unavailable |
LCID's revenue is currently healthy, but its profitability and cash flow are weak. There isn't enough data to rate its balance sheet.
SBH Fundamentals
| Metric | Status |
|---|---|
| Stable | |
| Healthy | |
| Healthy | |
| Healthy |
SBH's profitability, cash flow and balance sheet are currently healthy, and its revenue is stable.
LCID PE Valuation
LCID has no meaningful PE right now: it lost money over the past year.
SBH PE Valuation
| Level | PE | Price | Vs current |
|---|---|---|---|
| Cheap | 6.1x | $12.33 | -33% |
| Fair | 7.9x | $15.93 | -13% |
| Forward | 8.2x | $18.41 | — |
| Current | 9.1x | $18.41 | — |
| Expensive | 9.8x | $19.70 | +7% |
Historical ranges are pointers, not guarantees.
SBH's PE is in its expensive range at 9.1x. If earnings grow as analysts expect, today's price would be 8.2x next year's earnings, in its fair range.
LCID Forward outlook
| Metric | Outlook |
|---|---|
| -- | |
| Losses shrinking | |
| Strong growth | |
| -- | |
| Limited | |
| Low |
Analysts expect LCID's losses to shrink, with revenue growing. However, they disagree widely on these estimates.
SBH Forward outlook
| Metric | Outlook |
|---|---|
| Improving | |
| Growth | |
| Stable | |
| Improving | |
| Limited | |
| High |
Analysts expect SBH's earnings to grow and its profitability to improve, with its revenue holding steady.
LCID Earnings Per Share
| Quarter | TTM EPS | YoY |
|---|---|---|
| Q3 2026 | -$13.08 | -$2.57 |
| Q2 2026 | -$13.65 | -$2.35 |
| Q1 2026 | -$13.15 | -$1.25 |
| Q4 2025 | -$12.09 | +$0.41 |
| Q3 2025 | -$10.51 | +$2.49 |
| Q2 2025 | -$11.30 | +$0.40 |
| Q1 2025 | -$11.90 | +$0.40 |
| Q4 2024 | -$12.50 | +$1.10 |
LCID is still losing money, but less than at its worst: $13.08 per share over the past year, against $16.50 at its worst in mid-2023.
SBH Earnings Per Share
| Quarter | TTM EPS | YoY |
|---|---|---|
| Forward | $2.26 | +12% |
| Q3 2026 | $2.02 | +6.9% |
| Q2 2026 | $1.92 | +3.8% |
| Q1 2026 | $1.81 | +2.3% |
| Q4 2025 | $1.76 | +6% |
| Q3 2025 | $1.89 | +32% |
| Q2 2025 | $1.85 | +34% |
| Q1 2025 | $1.77 | +20% |
| Q4 2024 | $1.66 | +5.1% |
SBH has the edge over LCID on earnings quality, reporting a profit while its opponent remains loss making.
LCID Quarterly Revenue
| Quarter | Revenue | YoY |
|---|---|---|
| Q3 2026 | $350.3M | +4.1% |
| Q2 2026 | $405.3M | +56% |
| Q1 2026 | $282.5M | +20% |
| Q4 2025 | $522.7M | +123% |
| Q3 2025 | $336.6M | +68% |
| Q2 2025 | $259.4M | +29% |
| Q1 2025 | $235M | +36% |
| Q4 2024 | $234.5M | +49% |
LCID has the edge over SBH on sales, with more consistent year-over-year improvement.
| Quarter | Margin | YoY |
|---|---|---|
| Q3 2026 | -245% | +35 points |
| Q2 2026 | -267% | +43 points |
| Q1 2026 | -350% | -56 points |
| Q4 2025 | -204% | +109 points |
| Q3 2025 | -280% | +105 points |
| Q2 2025 | -310% | +83 points |
| Q1 2025 | -294% | +128 points |
| Q4 2024 | -313% | +156 points |
LCID's operating margin was −245% last quarter, up 35 points from the same quarter a year ago, near the top of its range since 2020.
SBH Quarterly Revenue
| Quarter | Revenue | YoY |
|---|---|---|
| Q3 2026 | $952.5M | +0.6% |
| Q2 2026 | $935.5M | +0.2% |
| Q1 2026 | $903.4M | +2.3% |
| Q4 2025 | $943.2M | +0.6% |
| Q3 2025 | $947.1M | +1.3% |
| Q2 2025 | $933.3M | -1% |
| Q1 2025 | $883.1M | -2.8% |
| Q4 2024 | $937.9M | +0.7% |
SBH's revenue has held roughly level: $953M last quarter, about level with the same quarter a year ago.
| Quarter | Margin | YoY |
|---|---|---|
| Q3 2026 | 9.7% | +1.2 points |
| Q2 2026 | 9.2% | +0.9 points |
| Q1 2026 | 8% | +0.1 points |
| Q4 2025 | 8.1% | -2.6 points |
| Q3 2025 | 8.4% | -0.4 points |
| Q2 2025 | 8.4% | +0.8 points |
| Q1 2025 | 7.9% | +1.3 points |
| Q4 2024 | 11% | +3.3 points |
SBH has the edge over LCID on profitability, with a higher operating margin.
LCID Free Cash Flow
| Quarter | Free cash flow | YoY |
|---|---|---|
| Q3 2026 | -$1B | -$84.2M |
| Q2 2026 | -$1.5B | -$463.2M |
| Q1 2026 | -$1.4B | -$849M |
| Q4 2025 | -$1.2B | -$417.1M |
| Q3 2025 | -$955.5M | -$333M |
| Q2 2025 | -$1B | -$271.6M |
| Q1 2025 | -$589.9M | +$125.1M |
| Q4 2024 | -$824.8M | -$77.6M |
LCID has burned cash in almost every quarter: −$5.2B over the past year, against −$3.4B the year before.
SBH Free Cash Flow
| Quarter | Free cash flow | YoY |
|---|---|---|
| Q3 2026 | $46.9M | -40% |
| Q2 2026 | $61.6M | +25% |
| Q1 2026 | $44.1M | +37% |
| Q4 2025 | $57.5M | +329% |
| Q3 2025 | $78M | +6.4% |
| Q2 2025 | $49.1M | +71% |
| Q1 2025 | $32.2M | +41% |
| Q4 2024 | $13.4M | -35% |
SBH has the edge over LCID on cash generation, producing positive trailing cash flow while its opponent burns cash.
LCID Total Shares
| Period | Change % | Net change |
|---|---|---|
| Quarterly | +3.3% | +12.5M shares |
| 1 year | +26% | +82.4M shares |
| 3 years | +73% | +166M shares |
LCID has 395M diluted shares, up 26% from a year ago.
| Quarter | Spent |
|---|---|
| Q4 2020 | $2.2M |
| Q1 2020 | — |
SBH Total Shares
| Period | Change % | Net change |
|---|---|---|
| Quarterly | +0.9% | +902K shares |
| 1 year | -4.8% | -5M shares |
| 3 years | -9.6% | -10.5M shares |
| 5 years | -13% | -15.4M shares |
| Available history | -16% | -18.3M shares |
SBH has the edge over LCID on shareholder dilution, with a more favorable share count trend.
| Quarter | Spent |
|---|---|
| Q3 2026 | $41.9M |
| Q2 2026 | $25.6M |
| Q1 2026 | $25.6M |
| Q4 2025 | $20.8M |
| Q3 2025 | $20.7M |
| Q2 2025 | $13.2M |
| Q1 2025 | $10.2M |
| Q4 2024 | $9.9M |
SBH spent $114M buying back its own shares over the past year, up 111% from the year before.
LCID Net Leverage
LCID's operating earnings (EBITDA) were negative over the past year, so its debt can't be measured against them.
SBH Net Leverage
| Quarter | Net Leverage | Status |
|---|---|---|
| Q3 2026 | 1.5x | Healthy |
| Q2 2026 | 1.5x | Healthy |
| Q1 2026 | 1.7x | Healthy |
| Q4 2025 | 1.7x | Healthy |
| Q3 2025 | 1.7x | Healthy |
| Q2 2025 | 1.8x | Healthy |
| Q1 2025 | 1.9x | Healthy |
| Q4 2024 | 2.0x | Healthy |
SBH's net debt is about 1.5 years of its operating earnings (EBITDA), down from 1.7 years a year ago.
LCID Weekly Momentum
| Metric | Value | Status |
|---|---|---|
| RSI | 32.9 | Neutral |
| Stochastic | 7.1 | Oversold |
LCID's weekly RSI is 33 (neutral) and its Stochastic is 7 (oversold).
SBH Weekly Momentum
| Metric | Value | Status |
|---|---|---|
| RSI | 65.5 | Neutral |
| Stochastic | 72.0 | Neutral |
SBH's weekly RSI is 65 (neutral) and its Stochastic is 72 (neutral).
LCID PE vs Consumer Cyclical Sector
LCID has no meaningful PE right now: it lost money over the past year.
SBH PE vs Consumer Cyclical Sector
| Metric | SBH | Sector median | Relative |
|---|---|---|---|
| PE | 9.1x | 18x | 49% below |
| PE % | 76 | 47 | 29 pts above |
SBH is trading at 9.1x earnings, a 49% discount to the Consumer Cyclical sector's median of 18x.
LCID Weekly Moving Averages
| Moving average | MA price | Relative |
|---|---|---|
| 8 week MA | $3.53 | 7.9% below |
| 20 week MA | $4.88 | 33% below |
| 50 week MA | $7.33 | 56% below |
| 100 week MA | $15.4 | 79% below |
| 200 week MA | $31.9 | 90% below |
LCID is in a downtrend: it's below all five of its weekly moving averages, and 90% below its 200-week average.
SBH Weekly Moving Averages
| Moving average | MA price | Relative |
|---|---|---|
| 8 week MA | $17.3 | 6.5% above |
| 20 week MA | $16.4 | 13% above |
| 50 week MA | $15.2 | 21% above |
| 100 week MA | $13.2 | 39% above |
| 200 week MA | $12.6 | 46% above |
SBH has the edge over LCID on trend strength, trading above more of its moving averages.
LCID Yearly ROI
| Year | Start price | End price | ROI |
|---|---|---|---|
| 2020 | $98.9 | $100.4 | +1.5% |
| 2021 | $100.4 | $376.4 | +275% |
| 2022 | $376.4 | $67.0 | -82% |
| 2023 | $67.0 | $42.1 | -37% |
| 2024 | $42.1 | $32.0 | -24% |
| 2025 | $32.0 | $11.4 | -64% |
| 2026 YTD | $11.4 | $3.25 | -72% |
LCID has finished four years in a row lower, and it's down 72% so far in 2026.
SBH Yearly ROI
| Year | Start price | End price | ROI |
|---|---|---|---|
| 2020 | $18.1 | $12.7 | -30% |
| 2021 | $12.7 | $18.6 | +47% |
| 2022 | $18.6 | $12.5 | -33% |
| 2023 | $12.5 | $13.3 | +6.4% |
| 2024 | $13.3 | $10.8 | -18% |
| 2025 | $10.8 | $15.0 | +38% |
| 2026 YTD | $15.0 | $18.4 | +23% |
SBH has the edge over LCID on returns for 2026, with the stronger performance.